 |
|
Treatment of Cancer-Associated HypercalcemiaDouble-blind Comparison of Rapid and Slow Intravenous Infusion Regimens of Pamidronate Disodium and Saline Alone
Rasim Gucalp, MD;
Richard Theriault, DO;
Indrani Gill, MD;
Stefan Madajewicz, MD;
Robert Chapman, MD;
Rudolph Navari, MD;
Frederick Ahmann, MD;
Ken Zelenakas, MS;
Maika Heffernan, PhD;
Robert D. Knight, MD
Arch Intern Med. 1994;154(17):1935-1944.
Abstract
| |
Background
We assessed the effects of 60-mg single doses of pamidronate disodium compared with saline alone in the treatment of cancer-associated hypercalcemia.
Methods
After pretreatment hydration, patients with corrected serum calcium concentrations of 3.0 mmol/L (12 mg/dL) or greater secondary to cancer were randomized to double-blind treatment with a single infusion of pamidronate disodium, 60 mg, over either 4 or 24 hours or continued infusions of 0.9% saline alone (n=23 per group). Corrected serum calcium levels were measured daily for 7 days of inpatient evaluation.
Results
Response rates for both of the pamidronate regimens were significantly (P<.05) higher than that for saline alone. A complete response to treatment (corrected serum calcium concentration normalized) was observed for five (22%), 18 (78%), and 14 (61%) patients, respectively, who received saline alone, 4-hour infusion of pamidronate, and 24-hour infusion of pamidronate. There were no significant differences between the two pamidronate regimens. Median durations of complete response were 6, 6, and 11 days, respectively, and median times to relapse (includes complete plus partial responders and nonresponders) were 0, 7, and 7 days, respectively. Pamidronate was well tolerated as assessed by all clinical and laboratory measures, regardless of the time of infusion.
Conclusions
A 4-hour infusion of pamidronate disodium, 60 mg, was as safe and effective as a 24-hour infusion, and both were superior to saline alone in lowering corrected serum calcium concentrations in patients with cancer-associated hypercalcemia.
(Arch Intern Med. 1994;154:1935-1944)
Author Affiliations
From the Department of Oncology, Montefiore Medical Center, Bronx, NY (Dr Gucalp); Department of Breast and Gyneocologic Medical Oncology, M. D. Anderson Cancer Center, University of Texas, Houston (Dr Theriault); Division of Medical Oncology, Norris Cancer Hospital, USC Medical Center, Los Angeles (Dr Gill); Division of Medical Oncology, University Hospital, SUNY—Stony Brook (Dr Madajewicz); Department of Medical Oncology, Henry Ford Hospital, Detroit, Mich (Dr Chapman); Department of Medical Oncology, Baptist Medical Center—Princeton, Birmingham, Ala (Dr Navari); Section of Hematology and Oncology, Veterans Affairs Medical Center, Tucson, Ariz (Dr Ahmann); and Pharmaceuticals Division, Ciba-Geigy Co, Summit, NJ (Mr Zelenakas and Drs Heffernan and Knight).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Case of Resistant Hypercalcemia of Malignancy with a Proposed Treatment Algorithm
McMahan and Linneman
The Annals of Pharmacotherapy 2009;43:1532-1538.
ABSTRACT
| FULL TEXT
Common acute oncological emergencies: diagnosis, investigation and management
Walji et al.
Postgrad. Med. J. 2008;84:418-427.
ABSTRACT
| FULL TEXT
The evidence base of palliative medicine: is inpatient palliative medicine evidence-based?
Keeley et al.
Palliat Med 2007;21:623-627.
ABSTRACT
Multiple Myeloma: Diagnosis and Treatment
Rajkumar and Kyle
Mayo Clin Proc. 2005;80:1371-1382.
ABSTRACT
Systematic review of bisphosphonates for hypercalcaemia of malignancy
Saunders et al.
Palliat Med 2004;18:418-431.
ABSTRACT
Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid
Berenson and Hirschberg
The Oncologist 2004;9:319-329.
ABSTRACT
| FULL TEXT
The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy
Major
The Oncologist 2002;7:481-491.
ABSTRACT
| FULL TEXT
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
Berenson et al.
JCO 2002;20:3719-3736.
ABSTRACT
| FULL TEXT
Current Therapy for Multiple Myeloma
Rajkumar et al.
Mayo Clin Proc. 2002;77:813-822.
ABSTRACT
Inpatient palliative medicine is evidence based
Good and Stafford
Palliat Med 2001;15:493-498.
ABSTRACT
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Major et al.
JCO 2001;19:558-567.
ABSTRACT
| FULL TEXT
Guidelines for the treatment of hypercalcemia associated with malignancy
Nakashima
J Oncol Pharm Pract 1997;3:31-37.
ABSTRACT
Pamidronate for Cancer-Associated Hypercalcemia-Reply
Gucalp and Knight
Arch Intern Med 1995;155:642-645.
ABSTRACT
Pamidronate for Cancer-Associated Hypercalcemia
Anand and Anand
Arch Intern Med 1995;155:641-642.
ABSTRACT
PAMIDRONATE DISODIUM FOR CANCER-ASSOCIATED HYPERCALCEMIA
JWatch General 1994;1994:3-3.
FULL TEXT
|
